Blair Boehmer, MD
Ophthalmology · Indianapolis, INNPI 1134313638
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,000 of the $6,075 with a category attached, or 65.8%. Alcon accounts for 69.7% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2024 at $4,370 and has fallen 93.5% since, to $283 in 2025.
Across 80 payments — averaging $75.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$4K
- AbbVie$285
- Notal Vision, Inc.$243
- Regeneron Healthcare Solutions, Inc.$220
- Aerie Pharmaceuticals, Inc.$131
- Johnson & Johnson Surgical Vision, Inc.$122
- plus $840 from 13 others
Across 16 payments — averaging $7613.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Aerie Pharmaceuticals, Inc.$73K
- Alcon Research LLC$49K
What the payments were for
- Consulting fees$4,00066%
- Speaking & faculty fees$2434%
- Food & beverage$1,83230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 19 | $4,234 |
| AbbVie(2 entities) | 8 | $285 |
| Notal Vision, Inc. | 1 | $243 |
| Regeneron Healthcare Solutions, Inc. | 10 | $220 |
| Aerie Pharmaceuticals, Inc. | 2 | $131 |
| Johnson & Johnson Surgical Vision, Inc. | 6 | $122 |
| Mallinckrodt Hospital Products Inc. | 1 | $122 |
| Biotissue Holdings Inc. | 3 | $120 |
| Apellis Pharmaceuticals, Inc. | 4 | $101 |
| Tarsus Pharmaceuticals, Inc. | 4 | $91 |
| Dompe US, Inc. | 4 | $79 |
| Genentech USA, Inc. | 3 | $76 |
| Rayner Intraocular Lenses Limited | 3 | $62 |
| Amgen(2 entities) | 3 | $53 |
| Bausch & Lomb Americas Inc. | 2 | $42 |
| Kala Pharmaceuticals, Inc. | 3 | $38 |
| Coherus Oncology, Inc. | 1 | $23 |
| NEW World Medical,inc. | 2 | $17 |
| Novartis | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,075 in reported general payments places this provider in the 85th percentile of 266 ophthalmology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 40 | $1,472,313 |
| XdemvyLotilaner | 28 | $50,838 |
| Prednisolone Acetate | 913 | $30,746 |
| Doxycycline Monohydrate | 769 | $17,850 |
| LumiganBimatoprost | 36 | $16,256 |
| VyzultaLatanoprostene Bunod | 31 | $12,246 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 49 | $11,176 |
| Loteprednol Etabonate | 32 | $8,550 |
| CombiganBrimonidine Tartrate/Timolol | 16 | $5,843 |
| Doxycycline Hyclate | 217 | $4,474 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 50 | $4,167 |
| Ketorolac Tromethamine | 171 | $3,992 |
| Latanoprost | 445 | $3,322 |
| Fluorometholone | 35 | $2,919 |
| Ofloxacin | 173 | $2,796 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $79 | $1,472,31340 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $91 | $50,83828 claims |
| AbbVieLumigan, Combigan | $285 | $22,09952 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $42 | $12,24631 claims |
| AlconSimbrinza | $4,234 | $11,17649 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 266 ophthalmology providers in Indiana.
Other ophthalmology in Indianapolis
- Kevin WaltzIndianapolis$199K
- Janet HummerIndianapolis$96K
- Francis PriceIndianapolis$67K
- Michael OrrIndianapolis$26K
- Matthew FengIndianapolis$22K
- John LindIndianapolis$20K
- Shaohui LiuIndianapolis$19K
- John LatonaIndianapolis$18K
- William WhitsonIndianapolis$15K
- Thierry WilbrandtIndianapolis$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.